RDY
Price
$14.22
Change
+$0.06 (+0.42%)
Updated
Sep 26 closing price
Capitalization
11.75B
27 days until earnings call
VTRS
Price
$9.52
Change
+$0.03 (+0.32%)
Updated
Sep 26 closing price
Capitalization
11.1B
44 days until earnings call
Interact to see
Advertisement

RDY vs VTRS

Header iconRDY vs VTRS Comparison
Open Charts RDY vs VTRSBanner chart's image
Dr. Reddy's Laboratories
Price$14.22
Change+$0.06 (+0.42%)
Volume$1.21M
Capitalization11.75B
Viatris
Price$9.52
Change+$0.03 (+0.32%)
Volume$7.47M
Capitalization11.1B
RDY vs VTRS Comparison Chart in %
Loading...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RDY vs. VTRS commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RDY is a Buy and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (RDY: $14.22 vs. VTRS: $9.52)
Brand notoriety: RDY and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RDY: 112% vs. VTRS: 75%
Market capitalization -- RDY: $11.75B vs. VTRS: $11.1B
RDY [@Pharmaceuticals: Generic] is valued at $11.75B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $11.1B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.83B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RDY’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • RDY’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than RDY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RDY’s TA Score shows that 5 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • RDY’s TA Score: 5 bullish, 5 bearish.
  • VTRS’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, both RDY and VTRS are a bad buy in the short-term.

Price Growth

RDY (@Pharmaceuticals: Generic) experienced а -4.37% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was -3.84% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

RDY is expected to report earnings on Oct 24, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($11.7B) has a higher market cap than VTRS($11.1B). VTRS has higher P/E ratio than RDY: VTRS (236.20) vs RDY (18.54). RDY YTD gains are higher at: -9.379 vs. VTRS (-20.571). RDY has higher annual earnings (EBITDA): 98.1B vs. VTRS (-493.3M). RDY has more cash in the bank: 66.7B vs. VTRS (809M). VTRS has less debt than RDY: VTRS (14.8B) vs RDY (48.6B). RDY has higher revenues than VTRS: RDY (334B) vs VTRS (14.1B).
RDYVTRSRDY / VTRS
Capitalization11.7B11.1B105%
EBITDA98.1B-493.3M-19,886%
Gain YTD-9.379-20.57146%
P/E Ratio18.54236.208%
Revenue334B14.1B2,369%
Total Cash66.7B809M8,245%
Total Debt48.6B14.8B328%
FUNDAMENTALS RATINGS
RDY vs VTRS: Fundamental Ratings
RDY
VTRS
OUTLOOK RATING
1..100
6470
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
11
Undervalued
PROFIT vs RISK RATING
1..100
50100
SMR RATING
1..100
5296
PRICE GROWTH RATING
1..100
5959
P/E GROWTH RATING
1..100
541
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (11) in the null industry is significantly better than the same rating for RDY (77) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew significantly faster than RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (50) in the Pharmaceuticals Generic industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that RDY’s stock grew somewhat faster than VTRS’s over the last 12 months.

RDY's SMR Rating (52) in the Pharmaceuticals Generic industry is somewhat better than the same rating for VTRS (96) in the null industry. This means that RDY’s stock grew somewhat faster than VTRS’s over the last 12 months.

RDY's Price Growth Rating (59) in the Pharmaceuticals Generic industry is in the same range as VTRS (59) in the null industry. This means that RDY’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for RDY (54) in the Pharmaceuticals Generic industry. This means that VTRS’s stock grew somewhat faster than RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RDYVTRS
RSI
ODDS (%)
Bearish Trend 3 days ago
64%
Bullish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
50%
Bullish Trend 3 days ago
62%
Momentum
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 3 days ago
62%
MACD
ODDS (%)
Bearish Trend 3 days ago
59%
Bearish Trend 3 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 3 days ago
63%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
45%
Bearish Trend 3 days ago
62%
Advances
ODDS (%)
Bullish Trend 12 days ago
49%
Bullish Trend 10 days ago
69%
Declines
ODDS (%)
Bearish Trend 4 days ago
54%
Bearish Trend 6 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
68%
Aroon
ODDS (%)
Bullish Trend 3 days ago
43%
Bearish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QFLR32.850.19
+0.60%
Innovator Nasdaq-100 Managed Floor ETF
PQJA27.990.08
+0.30%
PGIM NASDAQ-100 BUFFER 12 ETF - JANUARY
TIPX19.26N/A
N/A
SPDR® Blmbg 1-10 Year TIPS ETF
FEUS72.11N/A
N/A
FlexShares ESG & Clmt US Lrg Cap Cr Idx
JDOC50.40N/A
N/A
JPMorgan Healthcare Leaders ETF

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+0.42%
COLL - RDY
29%
Poorly correlated
-0.69%
HROW - RDY
28%
Poorly correlated
+2.06%
VTRS - RDY
27%
Poorly correlated
+0.32%
AVDL - RDY
27%
Poorly correlated
+0.07%
AMPH - RDY
26%
Poorly correlated
+1.86%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+0.32%
ELAN - VTRS
54%
Loosely correlated
+3.65%
ZTS - VTRS
48%
Loosely correlated
+1.68%
AMRX - VTRS
44%
Loosely correlated
+1.56%
EBS - VTRS
43%
Loosely correlated
+1.95%
COLL - VTRS
38%
Loosely correlated
-0.69%
More